Catalent, a global contract manufacturer, has sought to reassure its customers following its $16.5 billion deal with Novo Holdings. In a letter sent Monday, CEO Alessandro Maselli emphasised that the company will continue operating as an independent full-service CDMO and
Samsung Biologics, a global contract development and manufacturing organization (CDMO), has secured a $1.24 billion contract manufacturing agreement with an unnamed Asia-based pharmaceutical company. The deal, which runs until December 2037, is the largest contract ever signed by a single
Pharma Tech Industries, a global provider of contract manufacturing and packaging services, has named Darrin T. Schellin as its new Chief Executive Officer. With over two decades of experience in the healthcare and pharmaceutical sectors, Schellin will lead the company
Nucleus RadioPharma has announced plans to build two new facilities in Mesa, Arizona, and Springhouse, Pennsylvania, totaling over 100,000 square feet. These sites will integrate research, development, and commercial production, providing key advantages for the radiopharmaceutical industry. The expansion seeks
VIVUNT has proudly announced the inauguration of its third manufacturing facility, dedicated to the production of sterile oncology drugs in both lyophilized and liquid vials. This state-of-the-art plant, located in León, Spain, leverages cutting-edge technology and adheres to stringent international
“The GLP-1 agonist market is seeing unprecedented growth, and we’re investing €900 million to capture a fair amount of that business,” says CordenPharma’s Dr Mimoun Ayoub, outlining the CDMO’s most ambitious expansion plan to date in response to surging demand
PharmaLogic Holdings Corp., a contract development and manufacturing organisation (CDMO) and radiopharmacy solutions provider, has announced the official opening of its new radiopharmaceutical production and research facility in Salt Lake City, Utah. The facility is designed to support the delivery
FibroBiologics and Charles River Laboratories have entered a master services agreement to develop and manufacture FibroBiologics’ fibroblast-based therapeutic product, CYWC628. This product is set to be used in a diabetic foot ulcer (DFU) clinical trial scheduled to begin in 2025.
Jon Reed, Head of Strategic Business Planning at Recipharm, recently shared insights into the CDMO’s latest innovations and market strategies. Speaking to the PharmaSource podcast at CPHI Milan, Jon explains how Recipharm, one of the largest CDMOs in the industry
Dexter Tjoa, CEO of Tjoapack, recently shared insights into the company’s evolution from a small Dutch contract packaging organisation (CPO) to a global player in pharmaceutical packaging. Celebrating its 35th anniversary, Tjoapack has strategically expanded its operations, most notably with
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
